* individual being considered to be confirmed covid-19 * direct contact with covid-19 infected person within 14 days prior to the 1st dose of the ip * individuals at high risk of exposure to sars-cov-2 * individuals with clinically significant abnormalities in clinical laboratory tests, ecgs, and chest x-ray during screening * individuals with fever within 72 hours prior to the 1st dose of the ip or suspected other infectious disease or symptoms associated with other infectious disease * individuals with serious medical or psychiatric disease * history of sars-cov or mers-cov infection * history of allergic reaction or hypersensitivity reactions to any of components of the ip * history of serious adverse events, serious allergic reaction or serious hypersensitivity reactions to vaccination * history of receiving organ or bone marrow transplant * suspected or history of drug abuse or alcohol abuse within 6 months prior to vaccination * history of vaccination against sars-cov, mers-cov, or sars-cov-2 * history of vaccination with test vaccine substance * treatment with immunosuppressants or immune modifying drugs * history of treatment with antipsychotics or opioid dependence * pregnant or lactating women * other reasons based on which the individual is considered to be ineligible for this study in the opinion of the investigator

* individual being considered to be confirmed covid-19 * direct contact with covid-19 infected person within 14 days prior to the 1st dose of the ip * individuals at high risk of exposure to sars-cov-2 * individuals with clinically significant abnormalities in clinical laboratory tests, ecgs, and chest x-ray during screening * individuals with fever within 72 hours prior to the 1st dose of the ip or suspected other infectious disease or symptoms associated with other infectious disease * individuals with serious medical or psychiatric disease * history of sars-cov or mers-cov infection * history of allergic reaction or hypersensitivity reactions to any of components of the ip * history of serious adverse events, serious allergic reaction or serious hypersensitivity reactions to vaccination * history of receiving organ or bone marrow transplant * suspected or history of drug abuse or alcohol abuse within 6 months prior to vaccination * history of vaccination against sars-cov, mers-cov, or sars-cov-2 * history of vaccination with test vaccine substance * treatment with immunosuppressants or immune modifying drugs * history of treatment with antipsychotics or opioid dependence * pregnant or lactating women * other reasons based on which the individual is considered to be ineligible for this study in the opinion of the investigator

individual being considered to be confirmed covid-19 direct contact with covid-19 infected person within 14 days prior to the 1st dose of the ip individuals at high risk of exposure to sars-cov-2 individuals with clinically significant abnormalities in clinical laboratory tests, ecgs, and chest x-ray during screening individuals with fever within 72 hours prior to the 1st dose of the ip or suspected other infectious disease or symptoms associated with other infectious disease individuals with serious medical or psychiatric disease history of sars-cov or mers-cov infection history of allergic reaction or hypersensitivity reactions to any of components of the ip history of serious adverse events, serious allergic reaction or serious hypersensitivity reactions to vaccination history of receiving organ or bone marrow transplant suspected or history of drug abuse or alcohol abuse within 6 months prior to vaccination history of vaccination against sars-cov, mers-cov, or sars-cov-2 history of vaccination with test vaccine substance treatment with immunosuppressants or immune modifying drugs history of treatment with antipsychotics or opioid dependence pregnant or lactating women other reasons based on which the individual is considered to be ineligible for this study in the opinion of the investigator

individual being considered to be confirmed covid-19 direct contact with covid-19 infected person within 14 days prior to the 1st dose of the ip individuals at high risk of exposure to sars-cov-2 individuals with clinically significant abnormalities in clinical laboratory tests, ecgs, and chest x-ray during screening individuals with fever within 72 hours prior to the 1st dose of the ip or suspected other infectious disease or symptoms associated with other infectious disease individuals with serious medical or psychiatric disease history of sars-cov or mers-cov infection history of allergic reaction or hypersensitivity reactions to any of components of the ip history of serious adverse events, serious allergic reaction or serious hypersensitivity reactions to vaccination history of receiving organ or bone marrow transplant suspected or history of drug abuse or alcohol abuse within 6 months prior to vaccination history of vaccination against sars-cov, mers-cov, or sars-cov-2 history of vaccination with test vaccine substance treatment with immunosuppressants or immune modifying drugs history of treatment with antipsychotics or opioid dependence pregnant or lactating women other reasons based on which the individual is considered to be ineligible for this study in the opinion of the investigator